
1. malar j. 2015 mar 25;14:129. doi: 10.1186/s12936-015-0642-2.

prevalence plasmodium falciparum anti-malarial resistance-associated
polymorphisms pfcrt, pfmdr1 pfnhe1 muheza, tanzania, prior to
introduction artemisinin combination therapy.

gadalla nb(1), tavera g(2)(3), mu j(4), kabyemela er(5), fried m(6), duffy pe(7),
s√° jm(8), wellems te(9).

author information: 
(1)laboratory malaria vector research, national institute allergy and
infectious diseases, nih, rockville, md, usa. nahla.gadalla@nih.gov.
(2)laboratory malaria vector research, national institute allergy and
infectious diseases, nih, rockville, md, usa. gloria.tavera@case.edu.
(3)case western reserve university school medicine, cleveland, oh, 44106, usa.
gloria.tavera@case.edu.
(4)laboratory malaria vector research, national institute allergy and
infectious diseases, nih, rockville, md, usa. jmu@niaid.nih.gov.
(5)muhimbili university health allied sciences, dar es salaam, tanzania.
earkabyemela@yahoo.com.
(6)laboratory malaria immunology vaccinology, national institute of
allergy infectious diseases, nih, rockville, md, usa. michal.fried@nih.gov.
(7)laboratory malaria immunology vaccinology, national institute of
allergy infectious diseases, nih, rockville, md, usa. patrick.duffy@nih.gov.
(8)laboratory malaria vector research, national institute allergy and
infectious diseases, nih, rockville, md, usa. jsa@niaid.nih.gov.
(9)laboratory malaria vector research, national institute allergy and
infectious diseases, nih, rockville, md, usa. twellems@niaid.nih.gov.

background: report chloroquine amodiaquine resistance pfcrt-svmnt
haplotype tanzania raises concern high-level resistance the
artesunate-amodiaquine combination treatment widely employed africa. mutations
in pfmdr1 multi-drug resistance gene may also associated resistance, 
and highly polymorphic microsatellite (ms-4760) pfnhe1 gene involved 
quinine susceptibility surveyed tanzania.
methods: total 234 samples collected 2003 - 2006 an
observational birth cohort young children muheza, tanzania analysed.
in children, 141 cases p. falciparum infections treated aq and
93 episodes treated qn. haplotypes pfcrt pfmdr1 determined 
by taqman assay, ms-4760 repeats pfnhe1 assessed nested pcr
amplification direct sequencing. parasite population diversity evaluated 
using microsatellite markers five different chromosomes.
results: pfcrt-cviet haplotype present alone 93.6% (219/234) the
samples study period; wild-type chloroquine- and
amodiaquine-sensitive haplotype pfcrt-cvmnk present 4.3% (10/234) the
samples; haplotypes present 2.1% (5/234) samples. no
significant change wild-type pfcrt-cvmnk prevalence evident the
4-year period study. pfcrt-svmnt haplotype associated high-level 
amodiaquine resistance detected study. pfmdr1 locus was
genotyped 178 samples. pfmdr1-yyny haplotype predominated in
67.4% (120/178) infections significantly associated the
pfcrt-cviet haplotype. samples carried wild-type pfmdr1-n1042 codon. 
ms-4760 repeat pfnhe1 locus displayed 12 distinct haplotypes ms-4760-1
predominating population. analysis haplotypes showed no
association particular haplotype quinine treatment outcome.
conclusion: pfcrt-cviet chloroquine resistance haplotype dominated the
collection p. falciparum samples muheza. pfcrt-svmnt haplotype, which
threatens efficacy amodiaquine reported time period
from korogwe, tanzania, 40 km muheza, detected. relative low
prevalence pfcrt-svmnt africa may result genetic factors
rendering p. falciparum less supportive haplotype south america
or regions.
trial registration: trial protocol number: 08-i-n064.

doi: 10.1186/s12936-015-0642-2 
pmcid: pmc4392636
pmid: 25890383  [indexed medline]

